Patent · US Active

Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors

US10961204B1 · kind B1 · utility

2Cited by
64References
18Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 29, 2020
Grant dateMar 30, 2021
Priority date
Expiry dateApr 29, 2040

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.